-
Purpose(Empty Backbone) Tetracycline inducible (2TO version) expression of guide RNA targeted to AAVS1 locus
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 86697 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepAAV-Puro_siKO
-
Backbone manufacturerLudovic Vallier
- Backbone size (bp) 9585
-
Modifications to backboneRemoved H1 TO and gRNA scaffold by digestion with BstBI and HincII. Replaced with a 2TO H1 promoter and gRNA scaffold.
-
Vector typeMammalian Expression, CRISPR
- Promoter H1 2TO
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Cloning Information
- Cloning method Restriction Enzyme
- 5′ sequencing primer CGAACGCTGACGTCATCAACC
- 3′ sequencing primer GGGCTATGAACTAATGACCCCG (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byH1-TO promoter taken from pSuperior Neo (oligoengine)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pAAV-Puro_siKO-2TO was a gift from Ludovic Vallier (Addgene plasmid # 86697 ; http://n2t.net/addgene:86697 ; RRID:Addgene_86697) -
For your References section:
Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of human development using hPSCs. Bertero A, Pawlowski M, Ortmann D, Snijders K, Yiangou L, Cardoso de Brito M, Brown S, Bernard WG, Cooper JD, Giacomelli E, Gambardella L, Hannan NR, Iyer D, Sampaziotis F, Serrano F, Zonneveld MC, Sinha S, Kotter M, Vallier L. Development. 2016 Dec 1;143(23):4405-4418. 10.1242/dev.138081 PubMed 27899508